Global Polycythemia Vera Drug Sales Market, By Type (Dasatinib, Idelalisib, Givinostat, M-009, and Others), By Application (Clinic, Hospital, Others), By Region (North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle-East & Africa (MEA) Trend Analysis, Competitive Market Share & Forecast, 2017-2027
Published:
August 2021
Report Code:
BWC20359
Available Format:
PDF PDF Icon
Pages:
141

polycythemia vera drug sales market report

1. Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary and Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary and Secondary Sources

2.3. Breakdown of Primary Research Respondents

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents, By Industry Participants

2.5. Key Questionnaire asked during Primary Interviews

2.6. Key Primary Responses

2.7. Market Size Estimation

2.8. Assumption for the Study

2.9. Market Breakdown & Data Triangulation

3.    Executive Summary

4.    Global Polycythemia Vera Drug Sales Market – Industry Insights

4.1. DROC Analysis

4.1.1.   Growth Drivers

4.1.2.   Restraints

4.1.3.   Opportunity

4.1.4.   Challenges

4.2. Recent Developments / Technical Landscape

4.3. Regulatory Framework

4.4. Porter’s Five Forces Analysis

4.5. Value Chain Analysis

4.6. PESTEL Analysis

4.7. Strategic Outlook

5.    Global Polycythemia Vera Drug Sales Market Overview

5.1. Market Estimates & Forecast by Value, 2017-2027

5.1.1.   By Value (USD Million)

5.2. Market Share & Forecast

5.2.1.   By Type

5.2.1.1. Datatinib

5.2.1.2. Idelalisib

5.2.1.3. Givinostat

5.2.1.4. M-009

5.2.1.5. Others

5.2.2.   By Application

5.2.2.1. Clinic

5.2.2.2. Hospital

5.2.2.3. Others

5.2.3.   By Region

5.2.3.1. North America

5.2.3.2. Europe

5.2.3.3. Asia-Pacific (APAC)

5.2.3.4. Latin America (LATAM)

5.2.3.5. Middle-East & Africa (MEA)

6.    North America Polycythemia Vera Drug Sales Market Overview

6.1. Market Size and Forecast

6.1.1.   By Value (USD Million), 2017-2027

6.2. Market Share and Forecast

6.2.1.   By Type

6.2.2.   By Application

6.2.3.   By Country

6.2.3.1. U.S.

6.2.3.2. Canada

7.    Europe Polycythemia Vera Drug Sales Market Overview

7.1.     Market Size and Forecast

7.1.1.   By Value (USD Million), 2017-2027

7.2.     Market Share and Forecast

7.2.1.   By Type

7.2.2.   By Application

7.2.3.   By Country

7.2.3.1.   Germany

7.2.3.2.   U.K.

7.2.3.3.   France

7.2.3.4.   Italy

7.2.3.5.   Spain

7.2.3.6.   Russia

7.2.3.7.   Netherlands

7.2.3.8.   Rest of Europe

8.    APAC Polycythemia Vera Drug Sales Market Overview

8.1.     Market Size and Forecast

8.1.1.   By Value (USD Million), 2017-2027

8.2.     Market Share and Forecast

8.2.1.   By Type

8.2.2.   By Application

8.2.3.   By Country

8.2.3.1.   China

8.2.3.2.   India

8.2.3.3.   Japan

8.2.3.4.   South Korea

8.2.3.5.   Rest of APAC

9.    LATAM Polycythemia Vera Drug Sales Market Overview

9.1.     Market Size and Forecast

9.1.1.   By Value (USD Million), 2017-2027

9.2.     Market Share and Forecast

9.2.1.   By Type

9.2.2.   By Application

9.2.3.   By Country

9.2.3.1.   Mexico

9.2.3.2.   Brazil

9.2.3.3.   Rest of LATAM

10.MEA Polycythemia Vera Drug Sales Market Overview

10.1.   Market Size and Forecast

10.1.1.                By Value (USD Million), 2017-2027

10.2.   Market Share and Forecast

10.2.1.                By Type

10.2.2.                By Application

10.2.3.                By Country

10.2.3.1.              Saudi Arabia

10.2.3.2.              UAE

10.2.3.3.              South Africa

10.2.3.4.              Rest of Europe

11.Competitive Landscape

11.1.1.                List of Key Producers and Their Offerings

11.1.2.                Market Share / Ranking Analysis (2020)

11.1.3.                Competitive Benchmarking, By Operating Parameters

12.COVID-19 Impact

12.1.             Future Impact

12.2.             Key Developments during COVID-19

12.3.             Impact on Market

12.3.1.                Different Scenario

12.3.2.                Impact on Companies

12.4.             Regional Impact

13.Key Strategic Recommendations

14.Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

14.1.             ANP Technologies, Inc.

14.2.             Bristol-Myers Squibb Company

14.3.             F. Hoffmann-La Roche Ltd.

14.4.             Galena Biopharma, Inc.

14.5.             Gilead Sciences, Inc.

14.6.             Italfarmaco S.p.A.

14.7.             Karus Therapeutics Limited

14.8.             miRagen Therapeutics, Inc.

14.9.             Nerviano Medical Sciences S.r.l.

14.10.          Novartis AG

14.11.          PharmaEssentia Corporation

14.12.          Teva Pharmaceutical Industries Ltd.

14.13.          Otsuka America Pharmaceutical

14.14.          Inc. Pharmaclon

14.15.          Alfarm

14.16.          GNC Vector

14.17.          Zydus Cadila Incyte Corp.

14.18.          Pfizer

14.19.          Eli Lilly and Company

14.20.          Other Prominent Players

 

 

WHY CHOOSE US

  • 24/7 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Coustom Research Service

    Ask the Analyst to customize an exclusive study to serve your research needs.

  • Quality & Accuracy

    offers best quality reports based on various authentic and accurate data findings.

  • Data Visualization

    As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization

  • Information security

    We never share your personal and confidential information. Your personal information is safe and secure with us.